Walbrook PR appointed by Motif Bio & Surgical Innovations
16 February 2016
Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM listed Motif Bio plc, which specialises in developing novel antibiotics, and Surgical Innovations Group plc, which designs and manufactures innovative medical technology for minimally invasive surgery.
Motif Bio is a clinic stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) including those caused by resistant strains such as MRSA and MDRSP that have become prevalent in patients in both the community and hospital settings. Motif is in discussion with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria
For more information visit the Company's website:�www.motifbio.com
Surgical Innovations specializes in the design and manufacture of innovative devices for use in minimally invasive surgery and industrial markets. Over the last two decades they have designed and manufactured a range of pioneering devices such as YelloPort +plus® laparoscopic instrument system, Logi® Range resposable laparoscopic instrument system, FastClamp laparoscopic clamping system and Quick® Range single use laparoscopic instrumentation.
For more information visit the Company's website:�www.sigroupplc.com